Public Health Experts Discuss Importance Of Implementing Guidelines, Improving Access To Treatment For MDR-TB

PLOS Blogs’ “Speaking of Medicine”: Inexcusable Excuses: Reluctance to Quickly Improve MDR-TB Treatment
Helena Huerga, clinician and epidemiologist working with Médecins Sans Frontières (MSF)’s Epicentre; Uzma Khan, clinician and public health professional at Interactive Research and Development (IRD); and KJ Seung, clinician and public health professional at Harvard Medical School and Partners In Health (PIH), discuss the importance of implementing the new WHO guidance for treating multidrug-resistant tuberculosis (MDR-TB), writing, “Programs must take up the advice of the WHO and update treatment regimens to take advantage of these new tools and provide the best care possible for their patients. It is time for action (and new drugs), not excuses” (10/24).

PLOS Blogs’ “Speaking of Medicine”: Combating MDR-TB: Bringing a Knife to a Gunfight
Animesh Sinha, physician with Médecins Sans Frontières, discusses the role of bedaquiline and delamanid in treating MDR-TB and stresses the importance of making both drugs widely available, writing, “These drugs are long-awaited reinforcements in a failing battle and should be made available to every physician managing MDR-TB patients; countries and global health actors must meet this challenge” (10/24).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.